Flurbiprofen derivatives in Alzheimer's disease: Synthesis, pharmacokinetic and biological assessment of lipoamino acid prodrugs

Bioconjugate Chemistry

Volumn 19, Issue 1, 2008, Pages 349-357

  Pignatello, Rosario ^a   Pantò, Valentina ^a   Salmaso, Stefano ^b   Bersani, Sara ^b   Pistarà, Venerando ^a   Kepe, Vladimir ^c   Barrio, Jorge R ^c   Puglisi, Giovanni ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMICAL STABILITY; CONTROLLED DRUG DELIVERY; GLYCOPROTEINS; NEURODEGENERATIVE DISEASES; PHARMACOKINETICS; PLASMA STABILITY; PROTEINS; TARGETED DRUG DELIVERY;

ACTIVE DRUGS; ALZHEIMERS DISEASE; AMYLOID PROTEINS; BIOLOGICAL ASSESSMENT; BRAIN DELIVERY; FLURBIPROFEN; IN-VITRO; LIPOPHILIC PRODRUGS; PRODRUGS; SYNTHESISED;

BRAIN;

2 [1 [6 [(2 FLUOROETHYL)(METHYL)AMINO] 2 NAPHTHYL]ETHYLIDENE]MALONONITRILE F 18; AMYLOID BETA PROTEIN; FLUORINE 18; FLURBIPROFEN; FLURBIPROFEN 2 (2 FLUORO 4 BIPHENYL)PROPIONIC ACID 2 (2 AMINODECANOYL)AMINOETHYL ESTER CONJUGATE; FLURBIPROFEN 2 (2 FLUORO 4 BIPHENYL)PROPIONIC ACID 2 (2 AMINODODECANOYL)AMINOETHYL ESTER CONJUGATE; FLURBIPROFEN 2 (2 FLUORO 4 BIPHENYL)PROPIONIC ACID 2 (2 AMINOHEXANOYL)AMINOETHYL ESTER CONJUGATE; FLURBIPROFEN 2 (2 FLUORO 4 BIPHENYL)PROPIONIC ACID 2 (2 AMINOOCTANOYL)AMINOETHYL ESTER CONJUGATE; FLURBIPROFEN 2 (2 FLUORO 4 BIPHENYL)PROPIONIC ACID 2 (2 AMINOTETRADECANOYL)AMINOETHYL ESTER CONJUGATE; LIPOAMINO ACID; PRODRUG; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONJUGATE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; INHIBITION KINETICS; LIPOPHILICITY; MOUSE; NONHUMAN;

EID: 38949181536     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc700312y     Document Type: Article

References (37)

1. Akiyama, H., Barger, S., Barnum, S., Bradt, B., Bauer, J., Cole, G. M., Cooper, N. R., Eikelenboom, P., Emmerling, M., Fiebich, B. L., Finch, C. E., Frautschy, S., Griffin, W. S. T., Hampel, H., Hull, M., Landreth, G., Lue, L.-F., Mrak, R., Mackenzie, I. R., McGeer, P. L., O'Banion, M. K., Pachter, J., Pasinetti, G., Plata-Salaman, C., Rogers, J., Rydel, R., Shen, Y., Streit, W., Strohmeyer, R., Tooyoma, I., van Muiswinkel, F. L., Veerhuis, R., Walker, D., Websterm, S., Wegrzyniak, B., Wenk, G., and Wyss-Coray, T. (2000) Inflammation and Alzheimer's disease. Neurobiol. Aging 21, 383-421.
2. Mrak, R. E., Sheng, J. G., and Griffin, W. S. (1995) Glial cytokines in Alzheimer's disease: review and pathogenic implications. Hum. Pathol. 26, 816-823.
3. Mrak, R. E., and Griffin, W. S. (2005) Potential inflammatory biomarkers in Alzheimer's disease. J. Alzheimer Dis. 8, 369-375.
4. Bate, C., Kempster, S., Last, V., and Williams, A. (2006) Interferon-gamma increases neuronal death in response to amyloid-beta1-42. J. Neuroinflammation 3, 7.
5. Siegel, D. A., Davies, P., Dobrenis, K., and Huang, M. (2006) Tomoregulin-2 is found extensively in plaques in Alzheimer's disease brain. J. Neurochem. 98, 34-44.
6. Prasad, K. N., Cole, W. C., and Prasad, K. C. (2002) Risk factors for Alzheimer's disease: role of multiple antioxidants, non-steroidal anti-inflammatory and cholinergic agents alone or in combination in prevention and treatment. J. Am. Coll. Nutr. 21, 506-522.
7. Yip, A. G., Green, R. C., Huyck, M., Cupples, L. A., Farrer, L. A., and MIRAGE Study Group. (2005) Nonsteroidal antiinflammatory drug use and Alzheimer's disease risk: the MIRAGE Study. BMC Geriatr. 5, 2
8. Martyn, C. (2003) Anti-inflammatory drugs and Alzheimer's Disease. BMJ 327, 353-354.
9. Price, D. (2003) Effect of NSAIDs on risk of Alzheimer Disease. BMJ 327, 752.
10. Agdeppa, E. D., Kepe, V., Petrič, A., Satyamurthy, N., Liu, J., Huang, S. C., Small, G. W., Cole, G. M., and Barrio, J. R. (2003) In vitro detection of (S)-naproxen and ibuprofen binding to plaques in the Alzheimer's brain using the positron emission tomography molecular imaging probe 2-(1-[6-[(2-[(18)F]fluoroethyl)(methyl)amino]-2-naphthyl]ethylidene) malononitrile. Neuroscience 117, 723-730.
11. Pasinetti, G. M. (2002) From epidemiology to therapeutic trials with anti-inflammatory drugs in Alzheimer's disease: the role of NSAIDs and cyclooxygenase in beta-amyloidosis and clinical dementia. J. Alzheimer Dis. 4, 435-445.
12. Gasparini, L., Ongini, E., and Wenk, G. (2004) Non-steroidal anti-inflammatory drugs (NSAIDs) in Alzheimer's disease: old and new mechanism of action. J. Neurochem. 91, 521-536.
13. Eriksen, J. L., Sagi, S. A., Smith, T. E., Weggen, S., Das, P., McLendon, D. C., Ozols, V. V., Jessing, K. W., Zavitz, K. H., Koo, E. H., and Golde, T. E. (2003) NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo. J. Clin. Invest. 112, 440-449.
14. Weggen, S., Eriksen, J. L., Das, P., Sagi, S. A., Wang, R., Pietrzik, C. U., Findlay, K. A., Smith, T. E., Murphy, M. P., Bulter, T., Kang, D. E., Marquez-Sterling, N., Golde, T. E., and Koo, E. H. (2001) A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity. Nature 414, 212-216.
15. Imbimbo, B. P. (2004) The potential role of non-steroidal antiinflammatory drugs in treating Alzheimer's disease. Exp. Opin. Invest. Drugs 13, 1469-1481.
16. Avramovich, Y., Amit, T., and Youdim, M. B. (2002) Non-steroidal anti-inflammatory drugs stimulate secretion of non-amyloidogenic precursor protein. J. Biol. Chem. 277, 31466-31473.
17. Gasparini, L., Ongini, E., Wilcock, D., and Morgan, D. (2005) Activity of flurbiprofen and chemically related anti-inflammatory drugs in models of Alzheimer's disease. Brain Res. Brain Res. Rev. 48, 400-408.
18. Hirohata, M., Ono, K., Naiki, H., and Yamada, M. (2005) Non-steroidal anti-inflammatory drugs have anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. Neuropharmacol. 49, 1088-1099.
19. Townsend, K. P., and Praticò, D. (2005) Novel therapeutic opportunities for Alzheimer's disease: focus on nonsteroidal anti-inflammatory drugs. FASEB J. 19, 1592-1601.
20. Doraiswamy, P. M., and Xiong, G. L. (2006) Pharmacological strategies for the prevention of Alzheimer's disease. Exp. Opin. Pharmacother. 7, 1-10.
21. Stock, N., Munoz, B., Wrigley, J. D., Shearman, M. S., Beher, D., Peachey, J., Williamson, T. L., Bain, G., Chen, W., Jiang, X., St-Jacques, R., and Prasit, P. (2006) The geminal dimethyl analogue of flurbiprofen as a novel Abeta(42) inhibitor and potential Alzheimer's disease modifying agent. Bioorg. Med. Chem. Lett. 16, 2219-2322.
22. Gasparini, L., Rusconi, L., Xu, H., Del Soldato, P., and Ongini, E. (2004) Modulation of beta-amyloid metabolism by non-steroidal anti-inflammatory drugs in neuronal cell cultures. J. Neurochem. 88, 337-348.
23. Toth, I. (1994) A novel chemical approach to drug delivery: lipid amino acid conjugates. J. Drug Targeting 2, 217-239.
24. Wong, A., and Toth, I. (2001) Lipid, sugar and liposaccharide based delivery systems. Curr. Med. Chem. 8, 1123-1136.
25. Pignatello, R., Guccione, S., Castelli, F., Sarpietro, M. G., Giurato, L., Lombardo, M., and Puglisi, and Toth, I. (2006) Enhancement of drug affinity for cell membranes by conjugation with lipoamino acids. II. Int. J. Pharm. 310, 53-63.
26. Pignatello, R., Maltese, A., Maugeri, F., and Bucolo, C. (2006) Enhancement of availability of cloricromene at brain level by a lipophilic prodrug. J. Pharm. Pharmacol. 58, 1001-1005.
27. Small, G. W., Kepe, V., Ercoli, L. M., Siddarth, P., Bookheimer, S. Y., Miller, K. J., Lavretsky, H., Burggren, A. C., Cole, G. M., Vinters, H. V., Thompson, P. M., Huang, S.-C., Satyamurthy, N., Phelps, M. E., and Barrio, J. R. (2006) PET of brain amyloid and tau in mild cognitive impairment. N. Engl. J. Med. 355, 2652-2663.
28. Gibbons, W. A., Hughes, R. A., Choralambous, M., Christodoulou, M., Szeto, A., Aulobaugh, A. E., Mascagni, P., and Toth, I. (1990) Synthesis, resolution and tructural elucidation of lipidic amino acids and their homo- and hetero-oligomers. Liebigs Ann. Chem. 1175-1183.
29. Perrin, D. D., Armarego, W. L. F., and Perrin, D. R. (1980) Purification of Laboratory Chemicals 2nd ed., Pergamon Press, Oxford.
30. Liu, J., Kepe, V., žabjek, A., Petrič, A., Padgett, H. C., Satyamurthy, N., and Barrio, J. R. (2007) High-yield, automated radiosynthesis of 2-1-{6-(2-(18)F-fluoroethyl)(methyl)amino-2-naphthyl}ethylidene)malononitrile (18)F-FDDNP) ready for animal or human administration. Mol. Imaging Biol. 9, 6-16.
31. Caliceti, P., Schiavon, O., and Veronese, F. M. (1999) Biopharmaceutical properties of uricase conjugated to neutral amphiphilic polymers. Bioconjugate Chem. 10, 638-646.
32. Klunk, W. E., Jacob, R. F., and Mason, R. P. (1999) Quantifying amyloid β-peptide (Aβ) aggregation using the Congo red-Aβ (CR-Aβ) spectrophotometric assay. Anal. Biochem. 26, 66-76.
33. LeVine, H. (1993) Thioflavine T interaction with synthetic Alzheimer's disease β-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci. 2, 404-410.
34. Pignatello, R., Jansen, G., Kathmann, I., Puglisi, G., and Toth, I. (1998) Lipoamino acid conjugates of methotrexate with antitumor activity. J. Pharm. Sci. 87, 367-371.
35. Pignatello, R., Puleo, A., Giustolisi, S., Cuzzocrea, S., Dugo, L., Caputi, A. P., and Puglisi, G. (2002) Cloricromene conjugates with short-chain alkylamino acids: synthesis and biological evaluation. Drug Dev. Res. 57, 115-121.
36. Pignatello, R., Puleo, A., Campisi, A., Acquaviva, R., and Puglisi, G. (2004) Improved antioxidant activity of lipophilic conjugates of idebenone with short and medium alkylamino acids. J. Drug Delivery Sci. Technol. 14, 181-186.
37. Agdeppa, E. D., Kepe, V., Liu, J., Flores-Torres, S., Satyamurthy, N., Petric, A., Cole, G. M., Small, G. W., Huang, S.-C., and Barrio, J. R. (2001) Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for b-amyloid plaques in Alzheimer's disease. J. Neurosci. 21, RC189.